Berlin (1)

Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3 (1)

Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3 (1)

Neuroendocrine Carcinoma, Grade 3 (1)

Neuroendocrine Tumor, Grade 3 and Disease Progression as Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1.) (1)

Poorly Differentiated Malignant Neuroendocrine Carcinoma (1)

Completed (1)

phase 2 (1)

AIO-Studien-gGmbH (1)

Assign Data Management and Biostatistics GmbH (1)

Novartis Pharmaceuticals (1)

everolimus (afinitor®) (1)

drug (1)

Other (1)

Interventional (1)

poorly differentiated malignant neuroendocrine carcinoma

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Completed

Berlin, Germany

Charité-Universitätsmedizin, Medizinische Klinik m. S. Hepatolog

Oct 27, 2020